Matt Phipps
Stock Analyst at William Blair
(2.35)
# 2,596
Out of 5,143 analysts
24
Total ratings
47.06%
Success rate
2.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Outperform | n/a | $6.00 | - | 1 | Jan 5, 2026 | |
| EVMN Evommune | Initiates: Outperform | n/a | $27.88 | - | 1 | Dec 1, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.76 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $6.36 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $158.62 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $11.47 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.38 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $2.48 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $11.81 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $29.40 | - | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.52 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.92 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.65 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.27 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $61.60 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.65 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.49 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $195.13 | - | 2 | Jun 8, 2021 |
Compass Therapeutics
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $6.00
Upside: -
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $27.88
Upside: -
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.76
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $6.36
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $158.62
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $11.47
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.48
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.81
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $29.40
Upside: -
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.52
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.92
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $11.65
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $14.27
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $61.60
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.65
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.49
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $195.13
Upside: -